Hims & Hers Health (NYSE:HIMS) Raised to “Neutral” at Bank of America

Hims & Hers Health (NYSE:HIMS) was upgraded by research analysts at Bank of America from an “underperform” rating to a “neutral” rating in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a $23.00 price target on the stock, up from their prior price target of $12.50. Bank of America‘s target price would suggest a potential upside of 3.98% from the company’s previous close.

A number of other brokerages have also issued reports on HIMS. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. TD Cowen lowered their target price on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a report on Tuesday, February 24th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Truist Financial reaffirmed a “hold” rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Finally, Morgan Stanley lowered their target price on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $29.70.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $22.12 on Tuesday. Hims & Hers Health has a one year low of $13.74 and a one year high of $70.43. The firm has a market cap of $5.04 billion, a price-to-earnings ratio of 43.37, a P/E/G ratio of 3.01 and a beta of 2.56. The stock’s fifty day moving average price is $24.51 and its two-hundred day moving average price is $37.89. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. During the same quarter last year, the company earned $0.11 EPS. The company’s revenue was up 28.4% on a year-over-year basis. On average, equities analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a share buyback plan on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 3% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the sale, the chief operating officer owned 305,161 shares of the company’s stock, valued at $11,202,460.31. This represents a 4.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Irene Becklund sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the transaction, the insider directly owned 2,126 shares in the company, valued at $78,045.46. This trade represents a 79.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 80,463 shares of company stock valued at $2,846,696 over the last quarter. Company insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Pathway Capital Management LP purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth $6,766,000. Steadview Capital Management LLC boosted its position in shares of Hims & Hers Health by 80.0% in the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock worth $39,809,000 after purchasing an additional 311,845 shares during the period. State of Michigan Retirement System increased its stake in Hims & Hers Health by 49.2% in the 3rd quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock worth $116,713,000 after buying an additional 678,600 shares in the last quarter. Carnegie Investment Counsel boosted its stake in shares of Hims & Hers Health by 25.4% in the third quarter. Carnegie Investment Counsel now owns 303,909 shares of the company’s stock worth $17,238,000 after acquiring an additional 61,560 shares during the period. Finally, BIT Capital GmbH raised its stake in Hims & Hers Health by 73.8% during the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after purchasing an additional 938,728 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Deal ends legal dispute and opens product distribution — Novo Nordisk agreed to drop current proceedings and will distribute Wegovy and Ozempic on Hims’ platform, removing a major regulatory/legal overhang and creating a direct revenue and margin runway for Hims. Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
• Positive Sentiment: Market confirmation and coverage — Major outlets (CNBC, Yahoo, Bloomberg) reported the truce and distribution plan, accelerating institutional and retail buying as the revenue path became clearer. Hims & Hers shares surge after Novo Nordisk ends legal feud
• Positive Sentiment: Analyst upgrade — Needham upgraded HIMS from Hold to Buy with a $30 target, signaling buy‑side support and providing a fresh price catalyst. Benzinga coverage of Needham upgrade
• Neutral Sentiment: Short interest and squeeze dynamics — Commentators note very high short interest and the potential for an additional short squeeze; that can amplify gains but also increases volatility and downside risk when the squeeze unwinds. Seeking Alpha: Short squeeze discussion
• Neutral Sentiment: Strategic concession details — Reporting indicates Hims agreed to stop advertising compounded GLP‑1s and to offer Novo products at parity with other telehealth channels; that reduces legal risk but may limit some prior channels/margins. Inc: Concession details
• Negative Sentiment: Ongoing legal and corporate risk — A shareholder/litigation investigation (Kahn Swick & Foti) into Hims’ officers and directors was announced, keeping potential governance and liability risk on the table despite the Novo settlement. Business Wire: KSF investigation
• Negative Sentiment: Profitability and sustainability concerns — Several outlets warn today’s rally may be unsustainable once the short squeeze pressure fades; fundamental recovery depends on successful commercialization and margin capture of Novo products. Invezz: Sustainability warning

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.